Pazopanib for Metastatic Renal Cell Carcinoma - Beyond the Abstract

The number of studies evaluating pazopanib for first-line therapy of metastatic renal cell carcinoma (mRCC) in the real-world setting is relatively low due to the short duration of pazopanib availability in comparison with sunitinib, another standard first-line drug for mRCC. 

The aim of this study was a retrospective analysis of mRCC patients treated with pazopanib based data from a national registry. The present cohort of patients is one of the largest retrospective cohorts from a single country with a homogeneous population. Median progression-free (PFS) and overall survival (OS) for the whole cohort were 12.9 months (95% CI 11.0–14.8) and 33.2 months (95% CI 29.9–36.4), respectively. One- and two-year OS probability was 83.3% (95% CI 79.4–87.2) and 63.0% (95% CI 57.2–68.8), respectively. For patients who had metastatic disease at first presentation (M1), cytoreductive nephrectomy was associated with better outcomes, especially OS:  median reached OS 31.4 months (95% CI 24.7–38.1) versus  15.3 months (95% CI 9.8–20.9) (p=0.002), respectively for M1 patients with (n=114) versus without (n=71) cytoreductive nephrectomy.

There was no statistically significant difference in PFS or OS between patients achieving partial response and those with stable disease as the best response. As pazopanib is infrequently used as a comparator in clinical trials with novel agents, these results may serve as a benchmark for evaluating new agents.

Written by:
Tomas Buchler, MD, PhD, Associate Professor of Oncology, Department of Oncology First Faculty of Medicine, Charles University and Thomayer Hospital, Czech Republic

Read the Abstract


Poprach A, Fiala O, Chloupkova R, Melichar B, Lakomy R, Petrakova K, Zemanova M, Kopeckova K, Slaby O, Studentova H, Kopecký J, Kiss I, Finek J, Dusek L,Buchler T. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. Anticancer Res. 2018 Jan;38(1):449-456.